Regadenoson for myocardial perfusion imaging: Is it safe?
Author:
- 1 October 2014
- journal article
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 21 (5) , 871-876
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- "First do no harm" revisitedBMJ, 2013
- Complete heart block associated with regadenoson: A real side effectJournal of Nuclear Cardiology, 2012
- Coronary vasospasm during a regadenoson stress testCardiology Journal, 2012
- A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney diseaseJournal of Nuclear Cardiology, 2012
- A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imagingJournal of Nuclear Cardiology, 2011
- Adenosine A2A receptor gene polymorphism (1976C>T) affects coronary flow reserve response during vasodilator stress testing in patients with non ischemic-dilated cardiomyopathyPharmacogenetics and Genomics, 2011
- Capillary Supply to the Sinus Node in Subjects with Long-Term Atrial FibrillationThe Annals of Thoracic Surgery, 2010
- Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitusAmerican Heart Journal, 2009
- Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion ImagingJACC: Cardiovascular Imaging, 2008
- Locations of Coronary Artery Lesions in Patients With Severe Conduction DisturbanceInternational Heart Journal, 2008